Prostate Cancer Screening Guidelines in 2017
|
|
- Lorraine Howard
- 6 years ago
- Views:
Transcription
1 Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital
2 Prostate Specific Antigen (PSA)
3 Prostate Specific Antigen (PSA) Androgen-regulated protease enzyme Function : liquefy semen Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2002;2(12):
4 Prostate Specific Antigen (PSA) Normally found in low concentration in serum (ng/ml) Within serum, PSA circulates in bound (complexed PSA) and unbound (free PSA [fpsa]) forms Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:
5 Prostate Specific Antigen (PSA) PSA produced from malignant cells serum complexed PSA escape proteolytic processing free PSA Woodrum DL, Brawer MK, Partin AW, et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5 12.
6 Prostate Specific Antigen (PSA) Highly organ specific Primarily produced by prostatic luminal cells Not cancer specific Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:
7 Elevated serum PSA Disruption of cellular architecture within the prostate gland Barrier loss (prostate disease): BPH, prostatitis, prostate cancer Prostate manipulation: prostate massage, long distance bicycle riding Urinary retention Prostatic trauma: prostate biopsy Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317: Mejak SL, Bayliss J, Hanks SD. Long distance bicycle riding causes prostatespecific antigen to increase in men aged 50 years and over. PLoS One 2013;8:e56030.
8 Prostate Specific Antigen (PSA) The 5α-reductase inhibitors (5ARI), such as finasteride and dutasteride, lower PSA levels 50% after 12 months of treatment Doubling rule May overestimate PSA values in the first 6 months of treatment and underestimate PSA levels after several years of treatment Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993;22: Marks LS, Andriole GL, Fitzpatrick JM, et al. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 2006;176:
9 Early Detection and Screening
10 Early Detection and Screening Detection of disease at an early, pre-symptomatic stage when a man would have no reason to seek medical care An intervention referred to as secondary prevention In the US, early detection by PSA-based screening followed by prostate biopsy for diagnostic confirmation Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:
11 Benefits of PSA Screening
12 Benefits of PSA Screening Lower stage and grade of cancer at diagnosis Reduction in prostate cancer specific mortality rates Aus G, Bergdahl S, Lodding P et al: Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer results from a prospective, population based randomized controlled trial. Eur Urol 2007; 51: 659. Schröder FH, Hugosson J, Carlsson S et al: Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012; 62: 745. Labrie F, Canda sb, Cusan L et al: Screening decreases prostate cancer mortality: 11-year follow up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311.
13 Why the recommendation against screening for prostate cancer?
14 Why the recommendation against screening for prostate cancer? Screening and consequent treatment, as currently practiced, are often harmful: Too much screening of elderly men with a short life expectancy Too liberal criteria for biopsy Too aggressive treatment of low risk cancers Inadequate treatment of high risk cancers Treatment largely administered by low volume providers (higher risks of side effects and lower risks of cure) Vickers AJ, Lilja H. Time for another rethink on prostate cancer screening. Nat Rev Clin Oncol. 2011; 9:7-8.
15
16 Overdiagnosis The detection of a prostate cancer that would have remained undetected during life in the absence of screening
17 Overdiagnosis Of all screen-detected cancers, an estimated 10-56% would not have become apparent or caused symptoms in the patients lifetimes. Draisma G, Etzioni R,Tsodikov et al. Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. J Natl Cancer Inst 2009;101: Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:
18 Harms: Prostate biopsy Study population 5% random sample of Medicare participants, (n = 17,472) 30-day hospitalization rate (%) Infection Bleeding Not reported Urinary obstruction Not reported 30-day mortality rate (%) 0.31 All men receiving an initial prostate biopsy not resulting in diagnosis of cancer in Ontario, Canada, (n=41,682) Consecutive patients at a single academic medical center, (n = 1,000) Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186: Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183: Pinkhasov GI, Lin YK, Palmerola R, Smith P, Mahon F, Kaag MG, Dagen JE, Harpster LE, Reese CT, Raman JD. Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int 2012;110:
19 Harms Psychological impact of prostate cancer screening Distress involved in the decision making process, the biopsy and deciding among treatment options Severe psychological stress with one study showing an increased rate of suicide and cardiovascular events in newly diagnosed men Fang F et al: Immediate Risk of Suicide and Cardiovascular Death After a Prostate Cancer Diagnosis: Cohort Study in the United States. JNCI 2010; 102: 307.
20 PSA Screening and Overdiagnosis Claire L. Tonry et al. The role of proteomics in biomarker development for improved patient diagnosis and clinical decision making in prostate cancer. Diagnostics 2016, 6, 27. Roobol, M.J.; Carlsson, S.V. Risk stratification in prostate cancer screening. Nat. Rev. Urol. 2013, 10,
21 Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostatespecific antigen screening. N Engl J Med 2012;367:
22 PSA Screening Guidelines
23 PSA Screening Guidelines AUA EAU NCCN
24 PSA Screening Guidelines AUA EAU NCCN
25
26
27
28
29
30
31
32 Early Detection Guidelines: AUA 2013 For men ages 55 to 69 years Weighing the benefits of preventing prostate cancer mortality in 1 man for every 1,000 men screened over a decade against the known potential harms associated with screening and treatment Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:
33 Early Detection Guidelines: AUA Recommends against PSA screening in men under age 40 years 2. Does not recommend routine screening for men years at average risk (Family History, African-American) 3. Strongly recommends shared decision making for men years 4. Screening interval should be 2 years 5. Does not recommend routine screening for men 70 years or those with year life expectancy Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:
34 PSA Screening Guidelines AUA EAU NCCN
35
36
37
38
39
40 PSA Screening Guidelines AUA EAU NCCN
41 NCCN Guidelines years
42 Percent free PSA<10%, PHI>35 or 4K score Multiparametric MRI
43 Conclusion How to Increase the Benefits and Reduce the Risks of Screening for Prostate Cancer Risk-adjust screening by age and PSA (reduce false positives) Reduce false positive PSA results by repeating (verifying) positives and by adding additional markers (4Kpanel or -2(pro)PSA) (reduce indications for biopsy) Active surveillance for low-risk cancers (reduce harms of unnecessary therapy) Refer patients who need treatment to high-volume physicians or centers (reduce harm of necessary therapy) Vickers A, Roobol M, Lilja H. Annu. Rev. Med :
44 Thank You
Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationQuestions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test
Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test About Cancer Care Ontario s recommendations for prostate-specific antigen (PSA) screening 1. What does Cancer
More informationProstate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto
Prostate Cancer Screening: Con Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto / Why not PSA screening? Overdiagnosis Overtreatment Risk benefit ratio unfavorable Flaws of PSA
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationClinical Policy Title: Prostate-specific antigen screening
Clinical Policy Title: Prostate-specific antigen screening Clinical Policy Number: 13.01.06 Effective Date: May 1, 2017 Initial Review Date: April 19, 2017 Most Recent Review Date: April 19, 2017 Next
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationTable 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups
Oncology Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort Umberto Capitanio, Paul Perrotte, Laurent Zini, Nazareno Suardi, Elie Antebi,
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationPSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine
PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose
More informationTITLE: The Influence of Patient Heterogeneity on the Harms and Benefits of Prostate Cancer Screening
TITLE: The Influence of Patient Heterogeneity on the Harms and Benefits of Prostate Cancer Screening RUNNING HEAD: Patient Heterogeneity in Prostate Cancer Screening June 17, 2016 Daniel J. Underwood,
More informationExamining the Efficacy of Screening with Prostate- Specific Antigen Testing in Reducing Prostate Cancer Mortality
St. Catherine University SOPHIA Master of Arts/Science in Nursing Scholarly Projects Nursing 5-2012 Examining the Efficacy of Screening with Prostate- Specific Antigen Testing in Reducing Prostate Cancer
More information#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats
Prostate cancer is a VERY COMMON DISEASE BREAKTHROUGHS IN THE DETECTION OF PROSTATE CANCER Carolyn M. Fronczak M.D., M.S.P.H. Urologic Surgery 303-647-9129 #1 cancer #2 killer Ca Cancer J Clin 2018;68:7
More informationOriginal Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.249 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.249&domain=pdf&date_stamp=2014-04-17
More informationPSA Screening for Prostate Cancer at Western Medical Clinic Kardy Fedorowich University of Manitoba Max Rady College of Medicine
PSA Screening for Prostate Cancer at Western Medical Clinic Kardy Fedorowich University of Manitoba Max Rady College of Medicine Abstract While PSA screening for prostate cancer remains a widely used tool
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 12 References...
More informationEnzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum
Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum FOR RESEARCH USE ONLY Store at 2 to 8 C. PROPRIETARY AND COMMON NAMES f-psa Enzyme Immunoassay
More informationShould A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests?
Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests? Hanan Goldberg, MD Princess Margaret Cancer Centre, UHN, Sunnybrook Health science Centre, University of Toronto, Toronto,
More informationThe role of PSA in detection and management of prostate cancer
The role of PSA in detection and management of prostate cancer Kirby R. The role of PSA in detection and management of prostate cancer. Practitioner 2016; 260(1792):17-21 Professor Roger Kirby MA MD FRCS
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationPSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationDistribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer
Urological Oncology CHUN et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer Felix K.-H. Chun, Georg C.
More informationElsevier Editorial System(tm) for European Urology Manuscript Draft
Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article
More informationThe Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017
The Evolving Role of PSA for Prostate Cancer Adele Marie Caruso, DNP, CRNP Adult Nurse Practitioner Perelman School of Medicine at the University of Pennsylvania November 4, 2017 The Evolving Role of PSA
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationTitle: Prostate Specific Antigen (PSA) for Prostate Cancer Screening: A Clinical Review
Title: Prostate Specific Antigen (PSA) for Prostate Cancer Screening: A Clinical Review Date: November 26, 2007 Context and policy issues: Prostate cancer is the most common tumor in men, and is one of
More informationAge-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients
(2003) 6, 256 260 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients 1, *
More informationJ Clin Oncol 30: by American Society of Clinical Oncology
VOLUME 30 NUMBER 24 AUGUST 20 2012 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology
More informationProstatic Diseases and Male Voiding Dysfunction
Prostatic Diseases and Male Voiding Dysfunction Prostatic-specific Antigen Velocity After Holmium Laser Enucleation of the Prostate: Possible Predictor for the Assessment of Treatment Effect Durability
More informationProstate Cancer Screening. Eric Shreve, MD Bend Urology Associates
Prostate Cancer Screening Eric Shreve, MD Bend Urology Associates University of Cincinnati Medical Center University of Iowa Hospitals and Clinics PSA Human kallikrein 3 Semenogelin is substrate Concentration
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationWhat to Do with an Abnormal PSA Test. Feinberg School of Medicine, Chicago, Illinois, USA
The Oncologist Genitourinary Cancer What to Do with an Abnormal PSA Test STACY LOEB, a WILLIAM J. CATALONA b a Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; b The Northwestern
More informationProstate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence
DOI:10.1093/jnci/dju010 First published online March 4, 2014 The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. Commentary
More informationPSA as a Screening Test - AGP' GP's Perspective
PSA as a Screening Test - AGP' GP's Perspective Chris Del Mar cdelmar@bond.edu.auedu au Member of the RACGP Red Book Committee Background: prostate cancer is serious 9 th ranked cause of disease burden
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationAmbulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer
Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer Luigi Benecchi, Anna Maria Pieri, Carmelo Destro Pastizzaro, and Michele Potenzoni OBJECTIVES METHODS RESULTS CONCLUSIONS
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 745 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Allison S. Glass, Matthew R. Cooperberg and
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationProstate Cancer Screening:
Prostate Cancer Screening: The Other Side of the Story Tracie Gadler RN, MSN, RNFA, NP-C (Edited by Carol Salem MD) Urologic Oncology Surgery Robotic Surgical Services Nurse Practitioner, Scripps Mercy
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationProstate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer
Volume 1, Number 3 ISSN: 1932-9245 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and
More informationProstate cancer screening: Attitudes and practices of family physicians in Ontario
Original research Prostate cancer screening: Attitudes and practices of family physicians in Ontario Christopher B. Allard, MD; * Shawn Dason; * Janis Lusis, MD; Anil Kapoor, MD, FRCSC * *McMaster Institute
More informationNomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/ml
ORIGINAL ARTICLE Oncology & Hematology http://dx.doi.org/10.3346/jkms.2014.29.3.338 J Korean Med Sci 2014; 29: 338-342 Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less
More informationORIGINAL ARTICLE. Omer Gokhan Doluoglu 1, Cavit Ceylan 2, Fatih Kilinc 1, Eymen Gazel 2, Berkan Resorlu 1, Oner Odabas 2
ORIGINAL ARTICLE Vol. 42 (2): 346-350, March - April, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0082 Is there any association between National Institute of Health category IV prostatitis and prostate-specific
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationMr Declan Cahill Consultant Urological Surgeon The Royal Marsden
Diagnosing prostate cancer Mr Declan Cahill Consultant Urological Surgeon 2 Marsden GP Education Day 22 February 2016 Should I have a PSA test? Can I have a PSA test? prostatecanceruk.org 4 83% raised
More informationAssociation of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer
Association of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer Jeffrey J. Tosoian,*, Stacy Loeb,*, Zhaoyong Feng, Sumit Isharwal, Patricia Landis, Debra J. Elliot,
More informationOncology: Prostate/Testis/Penis/Urethra
Oncology: Prostate/Testis/Penis/Urethra Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates Bimal
More informationHyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume
More informationBPH AND BEYOND. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD
BPH AND BEYOND B: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD Baylor Prostate Center, The Scott Department of Urology, Baylor College
More informationIntroduction. Growths in the prostate can be benign (not cancer) or malignant (cancer).
This information was taken from urologyhealth.org. Feel free to explore their website to learn more. Another trusted website with good information is the national comprehensive cancer network (nccn.org).
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationUSA Preventive Services Task Force PSA Screening Recommendations- May 2018
GPGU - NOTÍCIAS USA Preventive Services Task Force PSA Screening Recommendations- May 2018 Rationale Importance Prostate cancer is one of the most common types of cancer that affects men. In the United
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationReducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study
Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Luke Witherspoon MD MSc, Johnathan L. Lau BSc, Rodney H. Breau MD MSc, Christopher
More informationα-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;
More informationScreening for Prostate Cancer US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement US Preventive Services
More informationUtility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma
Disease Markers 19 (2003,2004) 287 292 287 IOS Press Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma V. Thakur a,, P.P. Singh b, M. Talwar c and U. Mukherjee
More informationDetermination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer
Original Article DOI: 10.21276/APALM.1254 Determination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer Vineeth* G Nair and M. H. Shariff Department of Pathology, Yenepoya
More informationMercy s Cancer Program 2014 Update
Mercy s Cancer Program 2014 Update Mercy Hospital & Medical Center is accredited Academic Comprehensive Cancer Program by the American College of Surgeon s Commission on Cancer. This study is directed
More informationPSA SCREENING FOR PROSTATE CANCER
Policy Paper on PSA SCREENING FOR PROSTATE CANCER Has the time come to reconsider structured population-based PSA screening for prostate cancer? 1 2 Table of contents Table of Contents 1 EXECUTIVE SUMMARY
More informationProstate Cancer Screening: Navigating the Controversy
Prostate Cancer Screening: Navigating the Controversy 2 William M. Hilton, Ian M. Thompson Jr., and Dipen J. Parekh Despite advances in diagnosis, treatment, and patient outcomes, prostate cancer remains
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationScreening for Prostate Cancer
clinical practice Screening for Prostate Cancer Richard M. Hoffman, M.D., M.P.H. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies
More informationOverdiagnosis. Making people sick in the pursuit of health Drs Gilbert Welch, Lisa Schwartz, Steven Woloshin
Overdiagnosis Making people sick in the pursuit of health Drs Gilbert Welch, Lisa Schwartz, Steven Woloshin Screening for prostate cancer «Screening for prostate cancer has become the poster child of overdiagnosis
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationDiagnosis and management of prostate cancer in the
Diagnosis and management of prostate cancer in the Jeremy Teoh ( 張源津 ) Assistant Professor, Department of Surgery, The Chinese University of Hong Kong. Email: jeremyteoh@surgery.cuhk.edu.hk Estimated age-standardised
More informationObjectives. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
More informationRelationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
ORIGINAL ARTICLE (2011) 14, 53 57 & 2011 Macmillan Publishers Limited All rights reserved 1365-7852/11 www.nature.com/pcan Relationship between initial PSA density with future PSA kinetics and repeat biopsies
More informationProstate Cancer Screening & Treatment Updates. Daniel Gilbert, D.O. 4/2017
Prostate Cancer Screening & Treatment Updates Daniel Gilbert, D.O. 4/2017 1 www.drgilberturology.com Prostate Cancer Screening 2 Disclosures, Sponsors & Locations Nothing to disclose, No sponsors Hospital
More informationCanadian Urological Association recommendations on prostate cancer screening and early diagnosis
CUA GUIDELINE Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Ricardo A. Rendon, MD 1 ; Ross J. Mason, MD 2 ; Karim Marzouk, MD 3 ; Antonio Finelli, MD
More informationDeveloping a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationProstate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต
Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต Prostate cancer Overview Diagnosis Treatment Lower urinary tract symptoms EPIDEMIOLOGY The most common
More informationOncology: Prostate/Testis/Penis/Urethra. Prostate Specific Antigen Testing Among the Elderly When To Stop?
Oncology: Prostate/Testis/Penis/Urethra Prostate Specific Antigen Testing Among the Elderly When To Stop? Edward M. Schaeffer,*, H. Ballentine Carter, Anna Kettermann, Stacy Loeb, Luigi Ferrucci, Patricia
More informationCost-effectiveness of a new urinary biomarkerbased risk score compared to standard of care in prostate cancer diagnostics a decision analytical model
Cost-effectiveness of a new urinary biomarkerbased risk score compared to standard of care in prostate cancer diagnostics a decision analytical model Siebren Dijkstra*, Tim M. Govers, Rianne J. Hendriks*,
More informationWhite Paper: To Screen or Not to Screen?
White Paper: To Screen or Not to Screen? Prof Chris Bangma, one of the ERSPC directors, sets this challenge for health authorities in the light of their recent study into the benefits of population based
More informationProstate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph
Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading
More informationProstate-Specific Antigen Testing in Tyrol, Austria: Prostate Cancer Mortality Reduction Was Supported by an Update with Mortality Data up to 2008
Prostate-Specific Antigen Testing in, Austria: Prostate Cancer Mortality Reduction Was Supported by an Update with Mortality Data up to 2008 The Harvard community has made this article openly available.
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationIn 2008, the United States Preventive Services
CMAJ Analysis CME Prostate-specific antigen screening can be beneficial to younger and at-risk men Monique J. Roobol PhD Msc, Chris H. Bangma MD PhD, Stacy Loeb MD In 2008, the United States Preventive
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Expected population impacts of discontinued prostate-specific antigen screening Permalink https://escholarship.org/uc/item/5fd7z6j0 Journal
More informationImplications of Prostate Specific Antigen and its Molecular Derivatives in the Management of Carcinoma Prostate
Review Article DOI: 10.17354/ijss/2015/327 Implications of Prostate Specific Antigen and its Molecular Derivatives in the Management of Carcinoma Prostate Sujan Narayan Agrawal 1, Chanjiv Singh 2, Sanwal
More informationResponse to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners
Response to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners October 2011 Cancer Incidence Statistics, 2011 CA: A Cancer
More informationSERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE. A. AMAYO and W.
22 EAST AFRICAN MEDICAL JOURNAL January 2004 The East African Medical Journal Vol. 81 No. 1 January 2004 SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE.
More informationEstimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice
Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice A microsimulation screening analysis Carlsson, Sigrid V.; de Carvalho, Tiago M.;
More informationThe Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy
Original Article World J Nephrol Urol. 2018;7(1):12-16 The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy Ragheed Saoud a, Albert El-Haj
More informationThe population of subjects which was statistically analyzed was the Intent-to-Treat population
Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression
More information